Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

OSI-774

Known as: OSI 774, OSI774 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
It has been reported that gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has the ability… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Erlotinib (Tarceva™, OSI-774), a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR), was evaluated in a… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE Epidermal growth factor receptor/human epidermal growth factor receptor 1 (EGFR/HER1) and ligand expression is frequently… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recombinant, humanized anti-vascular endothelial growth… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation inhibitor with single-agent antitumor… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the… Expand
Is this relevant?
Review
2002
Review
2002
There is a need for new, selective anticancer agents that differentiate between malignant and nonmalignant cells. The benefits of… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
PURPOSE To assess the feasibility of administering OSI-774, to recommend a dose on a protracted, continuous daily schedule, to… Expand
Is this relevant?